Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro
07 April 2014 - 1:00PM
Marketwired
Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead
Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro
MONTREAL, QC--(Marketwired - Apr 7, 2014) - Sunshine Biopharma
Inc. (OTCQB: SBFM), a pharmaceutical company focused on the
research, development and commercialization of drugs for the
treatment of various forms of cancer today announced that it has
resolved the two isomeric forms of its lead anticancer compound,
Adva-27a, and as a result the specific activity of the drug
candidate has increased 9.5-fold. Sunshine Biopharma had previously
announced that the concentration at which Adva-27a inhibited 50% of
the activity of Topoisomerase II (IC50) was 13.7 micromolar (see
press release issued on October 5, 2011). As a result of today's
development Adva-27a's IC50 has dropped 9.5-fold, to 1.44
micromolar. This implies that significantly lower quantities of the
drug can be used to achieve the same effect.
"Isomeric forms of a compound refer to the fact that the
compound has different arrangements of its atoms in space," said
Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine
Biopharma. "Isomeric forms do not have identical properties. In the
case of Adva-27a, the molecule exists in the alpha or beta form.
This is a lot like a person's left hand and right hand. While the
two hands look identical, they actually are not. They are mirror
images of each other but are not superimposable. The fact that they
are not superimposable means that they are not identical.
Similarly, the alpha and beta forms of Adva-27a are not
superimposable. The implications of all of this for our future
breast cancer and pancreatic cancer patients are lower therapeutic
dosages, which theoretically should result in reduced
side-effects."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a
small molecule that has recently been shown to be effective at
killing multidrug resistant breast cancer cells, small-cell lung
cancer cells, uterine sarcoma cells and pancreatic cancer cells
(Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432,
October 2012). Adva-27a is currently in the IND-Enabling stage of
development. The original U.S. patent covering Adva-27a was issued
on August 7, 2012 under U.S. patent number 8,236,935. The Company
is planning a Phase I clinical trial of Adva-27a for pancreatic
cancer in parallel to the Phase I clinical trial of Adva-27a for
multidrug resistant breast cancer to be conducted at McGill
University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
For Additional Information Contact: Camille Sebaaly CFO Sunshine
Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com